Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.
<h4>Background</h4>Parkinson disease (PD) psychosis (PDP) is a disabling non-motor symptom. Pharmacologic treatment is limited to pimavanserin, quetiapine, and clozapine, which do not worsen parkinsonism. A Food and Drug Administration black box warning exists for antipsychotics, suggest...
Main Authors: | Katherine Longardner, Brenton A Wright, Aljoharah Alakkas, Hyeri You, Ronghui Xu, Lin Liu, Fatta B Nahab |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0278262 |
Similar Items
-
Improving Medication Regimen Recommendation for Parkinson’s Disease Using Sensor Technology
by: Jeremy Watts, et al.
Published: (2021-05-01) -
Ondansetron for the treatment of Parkinson’s disease psychosis: Rationale and literature review
by: Jaslovleen Kaur, et al.
Published: (2023-01-01) -
Approach to the management of psychosis in Parkinson’s disease
by: Abhishek Lenka, et al.
Published: (2019-01-01) -
Clinical Utility of Deutetrabenazine as a Treatment Option for Chorea Associated with Huntington’s Disease and Tardive Dyskinesia
by: Frank S, et al.
Published: (2023-12-01) -
Cariprazine treatment in patients with psychosis related to Parkinson’s Disease: a case report.
by: M. Martín De Argila Lorente, et al.
Published: (2023-03-01)